Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation
Author(s)
Edmunds, Kim
Reeves, Penny
Tuffaha, Haitham
Galvao, Daniel
Newton, Rob
Spry, Nigel
Denham, James
Taaffe, Dennis R
Joseph, David
Lamb, David S
Chambers, Suzanne K
Scuffham, Paul
Year published
2019
Metadata
Show full item recordAbstract
Aim: Exercise for prostate cancer (PC) survivors has been shown to be effective in addressing metabolic function and associated comorbidities (eg, diabetes, cardiovascular disease, etc), as well as sarcopenia and significant functional impairment resulting from long‐term androgen deprivation. The aim of this study is to determine the cost‐effectiveness of a supervised exercise intervention for long‐term PC survivors who received radiation therapy and androgen deprivation therapy.
Method: We conducted a cost‐effectiveness analysis of a multi‐centre randomised controlled trial (RCT) of supervised exercise training (resistance ...
View more >Aim: Exercise for prostate cancer (PC) survivors has been shown to be effective in addressing metabolic function and associated comorbidities (eg, diabetes, cardiovascular disease, etc), as well as sarcopenia and significant functional impairment resulting from long‐term androgen deprivation. The aim of this study is to determine the cost‐effectiveness of a supervised exercise intervention for long‐term PC survivors who received radiation therapy and androgen deprivation therapy. Method: We conducted a cost‐effectiveness analysis of a multi‐centre randomised controlled trial (RCT) of supervised exercise training (resistance and aerobic) in long‐term PC survivors (>5 years post‐diagnosis) alongside the Trans‐Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) trial. Results: In comparison to usual care, the total cost of the intervention was $546 from a health care payer perspective. The incremental cost per QALY gain was $65 050 (2018 AUD). Conclusions: This is the first cost‐effectiveness analysis of a supervised exercise intervention for long‐term PC survivors after curative radiotherapy and adjuvant ADT. The results indicate the intervention is effective, but not cost‐effective at a generally accepted WTP of $50 000. Evidence to support cost savings from post‐intervention outcomes would potentially reveal greater benefits such as reduced health service utilisation, chronic disease, falls and fractures and contribute to a more comprehensive analysis and more favourable cost‐effectiveness outcome. Future research should address these deficits via a larger trial with longer follow up.
View less >
View more >Aim: Exercise for prostate cancer (PC) survivors has been shown to be effective in addressing metabolic function and associated comorbidities (eg, diabetes, cardiovascular disease, etc), as well as sarcopenia and significant functional impairment resulting from long‐term androgen deprivation. The aim of this study is to determine the cost‐effectiveness of a supervised exercise intervention for long‐term PC survivors who received radiation therapy and androgen deprivation therapy. Method: We conducted a cost‐effectiveness analysis of a multi‐centre randomised controlled trial (RCT) of supervised exercise training (resistance and aerobic) in long‐term PC survivors (>5 years post‐diagnosis) alongside the Trans‐Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) trial. Results: In comparison to usual care, the total cost of the intervention was $546 from a health care payer perspective. The incremental cost per QALY gain was $65 050 (2018 AUD). Conclusions: This is the first cost‐effectiveness analysis of a supervised exercise intervention for long‐term PC survivors after curative radiotherapy and adjuvant ADT. The results indicate the intervention is effective, but not cost‐effective at a generally accepted WTP of $50 000. Evidence to support cost savings from post‐intervention outcomes would potentially reveal greater benefits such as reduced health service utilisation, chronic disease, falls and fractures and contribute to a more comprehensive analysis and more favourable cost‐effectiveness outcome. Future research should address these deficits via a larger trial with longer follow up.
View less >
Conference Title
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume
15
Issue
S4
Subject
Oncology and carcinogenesis
Science & Technology
Life Sciences & Biomedicine